Roman C. Sarott

This paper develops KAT-TCIPs to induce cell death in diffuse large B cell lymphoma by redirecting p300 and CBP to activate programmed cell death genes repressed by BCL6.

The paper demonstrates the use of a photoswitchable cannabinoid, azo-THC-3, to suppress seizures in a mouse model by local photoactivation in the hippocampus, avoiding systemic side effects.

This paper develops a small molecule, TRAP-1, that activates mutant p53 by forming a ternary complex with BRD4, leading to p53 target gene upregulation and inhibition of cancer cell growth.

This paper develops a TR-FRET-based assay to measure ligand binding kinetics for CB1R and CB2R, finding that D77 enables accurate determination of on- and off-rates for various agonists and antagonists.

This study develops a bivalent small molecule, EB-TCIP, that relocalizes EWS/FLI1 to induce BCL6 target genes, demonstrating a strategy to target fusion oncoproteins in Ewing sarcoma.

This study develops potent and selective CK1α molecular glue degraders through scaffold hopping and structure-activity relationship analysis of a glutarimide-based library.

The paper identifies CRBN-dependent WEE1 molecular glue degraders through combinatorial library screening and medicinal chemistry, providing structural insights into kinase selectivity.

The paper develops bivalent molecules that convert kinase inhibitors into activators of proapoptotic genes, achieving selective killing of DLBCL cells with low cytotoxicity.

This paper introduces LUX-MS, a light-triggered optoproteomic technology to map surfaceome receptor interactions and nanoscale organization, revealing insights into intercellular signaling and drug action.